다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Clinical and molecular hepatology, v.28 no.3, 2022년, pp.408 - 424
Hui, Rex Wan-Hin (Department of Medicine, The University of Hong Kong, Hong Kong) , Mak, Lung-Yi (Department of Medicine, The University of Hong Kong, Hong Kong) , Seto, Wai-Kay (Department of Medicine, The University of Hong Kong, Hong Kong) , Yuen, Man-Fung (Department of Medicine, The University of Hong Kong, Hong Kong)
AI-Helper
Chronic hepatitis B (CHB) is a major cause of liver-related morbidity and mortality. Functional cure of CHB, defined as sustainable hepatitis B surface antigen (HBsAg) seroclearance, is associated with improved clinical outcomes. However, functional cure is rarely attainable by current treatment mod...
1 Polaris Observatory Collaborators Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study Lancet Gastroenterol Hepatol 2018 3 383 403 29599078
2 Seto WK Lo YR Pawlotsky JM Yuen MF Chronic hepatitis B virus infection Lancet 2018 392 2313 2324 30496122
3 Mak LY Seto WK Hui RW Fung J Wong DK Lai CL Fibrosis evolution in chronic hepatitis B e antigen-negative patients across a 10-year interval J Viral Hepat 2019 26 818 827 30895682
4 Yuen MF Wong DK Fung J Ip P But D Hung I HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma Gastroenterology 2008 135 1192 1199 18722377
5 Mak LY Seto WK Yuen MF Novel antivirals in clinical development for chronic hepatitis B infection Viruses 2021 13 1169 34207458
6 Blank A Markert C Hohmann N Carls A Mikus G Lehr T First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B J Hepatol 2016 65 483 489 27132172
7 Squires KE Mayers DL Bluemling GR Kolykhalov AA Guthrie DB Reddy P ATI-2173, a novel liver-targeted non-chainterminating nucleotide for hepatitis B virus cure regimens Antimicrob Agents Chemother 2020 64 e00836 20 32540975
8 Morrissey DV Lockridge JA Shaw L Blanchard K Jensen K Breen W Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs Nat Biotechnol 2005 23 1002 1007 16041363
9 Hui RWH Mak LY Seto WK Yuen MF Role of core/capsid inhibitors in functional cure strategies for chronic hepatitis B Curr Hepatology Rep 2020 19 293 301
10 Real CI Werner M Paul A Gerken G Schlaak JF Vaillant A Nucleic acid-based polymers effective against hepatitis B virus infection in patients don’t harbor immunostimulatory properties in primary isolated liver cells Sci Rep 2017 7 43838 28272460
11 Kao CC Nie Y Ren S De Costa NTTS Pandey RK Hong J Mechanism of action of hepatitis B virus S antigen transportinhibiting oligonucleotide polymer, STOPS, molecules Mol Ther Nucleic Acids 2021 27 335 348 35024245
12 Erken R Andre P Roy E Kootstra N Barzic N Girma H Farnesoid X receptor agonist for the treatment of chronic hepatitis B: a safety study J Viral Hepat 2021 28 1690 1698 34467593
13 Boni C Vecchi A Rossi M Laccabue D Giuberti T Alfieri A TLR7 agonist increases responses of hepatitis B virus-specific T cells and natural killer cells in patients with chronic hepatitis B treated with nucleos(t)ide analogues Gastroenterology 2018 154 1764 1777.e7 29378197
14 Gane E Verdon DJ Brooks AE Gaggar A Nguyen AH Subramanian GM Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study J Hepatol 2019 71 900 907 31306680
15 Fergusson JR Wallace Z Connolly MM Woon AP Suckling RJ Hine DW Immune-mobilizing monoclonal T cell receptors mediate specific and rapid elimination of hepatitis B-infected cells Hepatology 2020 72 1528 1540 32770836
16 Boni C Janssen HLA Rossi M Yoon SK Vecchi A Barili V Combined GS-4774 and tenofovir therapy can improve HBVspecific T-cell responses in patients with chronic hepatitis Gastroenterology 2019 157 227 241.e7 30930022
17 Lee HW Park JY Hong T Park MS Ahn SH A prospective, openlabel, dose-escalation, single-center, phase 1 study for GC1102, a recombinant human immunoglobulin for chronic hepatitis B patients Hepatology 2018 68 S1 453
18 Yeo YH Ho HJ Yang HI Tseng TC Hosaka T Trinh HN Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: a systematic review and meta-analysis Gastroenterology 2019 156 635 646.e9 30342034
19 Fire A Xu S Montgomery MK Kostas SA Driver SE Mello CC Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans Nature 1998 391 806 811 9486653
20 MacRae IJ Ma E Zhou M Robinson CV Doudna JA In vitro reconstitution of the human RISC-loading complex Proc Natl Acad Sci U S A 2008 105 512 517 18178619
21 Caplen NJ Parrish S Imani F Fire A Morgan RA Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems Proc Natl Acad Sci U S A 2001 98 9742 9747 11481446
22 Rivas FV Tolia NH Song JJ Aragon JP Liu J Hannon GJ Purified argonaute2 and an siRNA form recombinant human RISC Nat Struct Mol Biol 2005 12 340 349 15800637
23 Iwasaki S Kawamata T Tomari Y Drosophila argonaute1 and argonaute2 employ distinct mechanisms for translational repression Mol Cell 2009 34 58 67 19268617
24 Petersen CP Bordeleau ME Pelletier J Sharp PA Short RNAs repress translation after initiation in mammalian cells Mol Cell 2006 21 533 542 16483934
25 Verdel A Jia S Gerber S Sugiyama T Gygi S Grewal SI RNAi-mediated targeting of heterochromatin by the RITS complex Science 2004 303 672 676 14704433
26 Haley B Zamore PD Kinetic analysis of the RNAi enzyme complex Nat Struct Mol Biol 2004 11 599 606 15170178
27 Adams D Gonzalez-Duarte A O’Riordan WD Yang CC Ueda M Kristen AV Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis N Engl J Med 2018 379 11 21 29972753
28 Setten RL Rossi JJ Han SP The current state and future directions of RNAi-based therapeutics Nat Rev Drug Discov 2019 18 421 446 30846871
29 Jacque JM Triques K Stevenson M Modulation of HIV-1 replication by RNA interference Nature 2002 418 435 438 12087358
30 Kumar P Ban HS Kim SS Wu H Pearson T Greiner DL T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice Cell 2008 134 577 586 18691745
31 Bitko V Barik S Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses BMC Microbiol 2001 1 34 11801185
32 Gitlin L Stone JK Andino R Poliovirus escape from RNA interference: short interfering RNA-target recognition and implications for therapeutic approaches J Virol 2005 79 1027 1035 15613331
33 Geisbert TW Lee AC Robbins M Geisbert JB Honko AN Sood V Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-ofconcept study Lancet 2010 375 1896 1905 20511019
34 Levanova A Poranen MM RNA interference as a prospective tool for the control of human viral infections Front Microbiol 2018 9 2151 30254624
35 Jackson AL Linsley PS Recognizing and avoiding siRNA offtarget effects for target identification and therapeutic application Nat Rev Drug Discov 2010 9 57 67 20043028
36 Qiu S Adema CM Lane T A computational study of off-target effects of RNA interference Nucleic Acids Res 2005 33 1834 1847 15800213
37 Naito Y Ui-Tei K siRNA design software for a target genespecific RNA interference Front Genet 2012 3 102 22701467
38 Hickerson RP Vlassov AV Wang Q Leake D Ilves H Gonzalez-Gonzalez E Stability study of unmodified siRNA and relevance to clinical use Oligonucleotides 2008 18 345 354 18844576
39 Liao H Wang JH Biomembrane-permeable and ribonuclease-resistant siRNA with enhanced activity Oligonucleotides 2005 15 196 205 16201907
40 Sledz CA Holko M de Veer MJ Silverman RH Williams BR Activation of the interferon system by short-interfering RNAs Nat Cell Biol 2003 5 834 839 12942087
41 Alexopoulou L Holt AC Medzhitov R Flavell RA Recognition of double-stranded RNA and activation of NF-kappaB by toll-like receptor 3 Nature 2001 413 732 738 11607032
42 Czauderna F Fechtner M Dames S Aygün H Klippel A Pronk GJ Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells Nucleic Acids Res 2003 31 2705 2716 12771196
43 Jackson AL Burchard J Leake D Reynolds A Schelter J Guo J Position-specific chemical modification of siRNAs reduces “off-target” transcript silencing RNA 2006 12 1197 1205 16682562
44 Judge AD Bola G Lee AC MacLachlan I Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo Mol Ther 2006 13 494 505 16343994
45 Allerson CR Sioufi N Jarres R Prakash TP Naik N Berdeja A Fully 2’-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA J Med Chem 2005 48 901 904 15715458
46 Shen C Reske SN Adenovirus-delivered siRNA Methods Mol Biol 2004 252 523 532 15017078
47 Kaczmarek JC Kowalski PS Anderson DG Advances in the delivery of RNA therapeutics: from concept to clinical reality Genome Med 2017 9 60 28655327
48 Springer AD Dowdy SF GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics Nucleic Acid Ther 2018 28 109 118 29792572
49 Konishi M Wu CH Wu GY Inhibition of HBV replication by siRNA in a stable HBV-producing cell line Hepatology 2003 38 842 850 14512871
50 Boden D Pusch O Lee F Tucker L Ramratnam B Human immunodeficiency virus type 1 escape from RNA interference J Virol 2003 77 11531 11535 14557638
51 Kapadia SB Brideau-Andersen A Chisari FV Interference of hepatitis C virus RNA replication by short interfering RNAs Proc Natl Acad Sci U S A 2003 100 2014 2018 12566571
52 Buti M Rodriguez-Frias F Jardi R Esteban R Hepatitis B virus genome variability and disease progression: the impact of precore mutants and HBV genotypes J Clin Virol 2005 34 Suppl 1 S79 S82 16461229
53 Wu HL Huang LR Huang CC Lai HL Liu CJ Huang YT RNA interference-mediated control of hepatitis B virus and emergence of resistant mutant Gastroenterology 2005 128 708 716 15765406
54 Shih YM Sun CP Chou HH Wu TH Chen CC Wu PY Combinatorial RNA interference therapy prevents selection of preexisting HBV variants in human liver chimeric mice Sci Rep 2015 5 15259 26482836
55 Kayesh MEH Kohara M Tsukiyama-Kohara K Toll-like receptor response to hepatitis B virus infection and potential of TLR agonists as immunomodulators for treating chronic hepatitis B: an overview Int J Mol Sci 2021 22 10462 34638802
56 Fisicaro P Valdatta C Massari M Loggi E Biasini E Sacchelli L Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B Gastroenterology 2010 138 682 693 693.e1-e4 19800335
57 Stoop JN van der Molen RG Baan CC van der Laan LJ Kuipers EJ Kusters JG Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection Hepatology 2005 41 771 778 15791617
58 Le Bert N Gill US Hong M Kunasegaran K Tan DZM Ahmad R Effects of hepatitis B surface antigen on virus-specific and global T cells in patients with chronic hepatitis B virus infection Gastroenterology 2020 159 652 664 32302614
59 Park JJ Wong DK Wahed AS Lee WM Feld JJ Terrault N Hepatitis B virus--specific and global T-cell dysfunction in chronic hepatitis B Gastroenterology 2016 150 684 695.e5 26684441
60 Seto WK Cheung KS Wong DK Huang FY Fung J Liu KS Hepatitis B surface antigen seroclearance during nucleoside analogue therapy: surface antigen kinetics, outcomes, and durability J Gastroenterol 2016 51 487 495 26446756
61 Boni C Laccabue D Lampertico P Giuberti T Viganò M Schivazappa S Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues Gastroenterology 2012 143 963 973.e9 22796241
62 Sohail M Hochegger H Klotzbücher A Guellec RL Hunt T Southern EM Antisense oligonucleotides selected by hybridisation to scanning arrays are effective reagents in vivo Nucleic Acids Res 2001 29 2041 2051 11353073
63 Dhuri K Bechtold C Quijano E Pham H Gupta A Vikram A Antisense oligonucleotides: an emerging area in drug discovery and development J Clin Med 2020 9 2004
64 Miller CM Tanowitz M Donner AJ Prakash TP Swayze EE Harris EN Receptor-mediated uptake of phosphorothioate antisense oligonucleotides in different cell types of the liver Nucleic Acid Ther 2018 28 119 127 29425080
65 Dominska M Dykxhoorn DM Breaking down the barriers: siRNA delivery and endosome escape J Cell Sci 2010 123 Pt 8 1183 1189 20356929
66 Vocelle D Chan C Walton SP Endocytosis controls siRNA efficiency: implications for siRNA delivery vehicle design and cellspecific targeting Nucleic Acid Ther 2020 30 22 32 31718426
67 Linnane E Davey P Zhang P Puri S Edbrooke M Chiarparin E Differential uptake, kinetics and mechanisms of intracellular trafficking of next-generation antisense oligonucleotides across human cancer cell lines Nucleic Acids Res 2019 47 4375 4392 30927008
68 Gane E Yuen MF Kim DJ Chan HL Surujbally B Pavlovic V Clinical study of single-stranded oligonucleotide RO7062931 in healthy volunteers and patients with chronic hepatitis B Hepatology 2021 74 1795 1808 34037271
69 Liang XH Sun H Nichols JG Crooke ST RNase H1-dependent antisense oligonucleotides are robustly active in directing RNA cleavage in both the cytoplasm and the nucleus Mol Ther 2017 25 2075 2092 28663102
70 Liang XH Sun H Shen W Wang S Yao J Migawa MT Antisense oligonucleotides targeting translation inhibitory elements in 5’ UTRs can selectively increase protein levels Nucleic Acids Res 2017 45 9528 9546 28934489
71 Tallet-Lopez B Aldaz-Carroll L Chabas S Dausse E Staedel C Toulmé JJ Antisense oligonucleotides targeted to the domain IIId of the hepatitis C virus IRES compete with 40S ribosomal subunit binding and prevent in vitro translation Nucleic Acids Res 2003 31 734 742 12527783
72 Goodarzi G Gross SC Tewari A Watabe K Antisense oligodeoxyribonucleotides inhibit the expression of the gene for hepatitis B virus surface antigen J Gen Virol 1990 71 Pt 12 3021 3025 2177093
73 Wooddell CI Rozema DB Hossbach M John M Hamilton HL Chu Q Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection Mol Ther 2013 21 973 985 23439496
74 Wooddell CI Yuen MF Chan HL Gish RG Locarnini SA Chavez D RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg Sci Transl Med 2017 9 >eaan0241 28954926
75 Gane E Lim YS Cloutier D Shen L Cathcart A Ding X Safety and antiviral activity of VIR-2218, an X-targeting RNAi therapeutic, in participants with chronic hepatitis B infection: week 48 follow-up results J Hepatol 2021 75 S287 S288
76 Sterinu-Cercel A Gane E Cheng W Sievert W Roberts S Ahn SH A phase 2a study evaluating the multi-dose activity of ARB-1467 in HBeAg-positive and -negative virally suppressed subjects with hepatitis B J Hepatol 2017 66 S688 S689
77 Gane E Locarnini S Lim TH Strasser S Sievert W Cheng W Short interfering RNA JNJ-3989 combination therapy in chronic hepatitis B shows potent reduction of all viral markers but no correlate was identified for HBsAg reduction and baseline factors J Hepatol 2021 75 Suppl 2 S289 S290
78 Thi EP Dhillon AP Ardzinski A Bidirici-Ertekin L Cobarrubias KD Cuconati A ARB-1740, a RNA interference therapeutic for chronic hepatitis B infection ACS Infect Dis 2019 5 725 737 30403127
79 Wooddell C Zhu R Hamilton H Chu Q Sternard H Schumacher J Development of subcutaneously administered RNAi therapeutic ARO-HBV for chronic hepatitis B virus infection J Hepatol 2018 68 S18 S19
80 Durantel D Zoulim F New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus J Hepatol 2016 64 1 Suppl S117 S131 27084032
81 Schluep T Lickliter J Hamilton J Lewis DL Lai CL Lau JY Safety, tolerability, and pharmacokinetics of ARC-520 injection, an RNA interference-based therapeutic for the treatment of chronic hepatitis B virus infection, in healthy volunteers Clin Pharmacol Drug Dev 2017 6 350 362 27739230
82 Yuen MF Schiefke I Yoon JH Ahn SH Heo J Kim JH RNA interference therapy with ARC-520 results in prolonged hepatitis B surface antigen response in patients with chronic hepatitis B infection Hepatology 2020 72 19 31 31654573
83 Yuen MF Wong DK Schluep T Lai CL Ferrari C Locarnini S Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment Gut 2022 71 789 797 33712437
84 Agarwal K Gane E Cheng W Sievert W Roberts S Ahn SH Bi-weekly dosing of ARB-1467 LNP siRNA in HBeAgNegative, virally suppressed patients with chronic HBV infection leads to deeper declines in HBsAg and potential association with IL28b AASLD The Liver Meeting 2017 2017 Oct 20-24 Washington, DC, USA
85 Arbutus Biopharma. Arbutus reports fourth quarter and yearend 2018 financial results and describes recent clinical accomplishments and key 2019 objectives. Arbutus Biopharma web site, < https://investor.arbutusbio.com/news-releases/newsrelease-details/arbutus-reports-fourth-quarter-and-year-end2018-financial >. Accessed 15 Feb 2022
86 Yuen MF Berliba E Sukeepaisarnjaroen W Tangkijvanich P Leerapun A Holmes J Low HBsAg levels maintained following cessation of the GalNAc-siRNA, AB-729, in chronic hepatitis B patients on nucleos(t)ide analogue therapy AASLD The Liver Meeting 2017 2021 Nov 12-15 USA
87 Thi EP Yuen MF Gane E Sevinsky H Sims K Anderson M Inhibition of hepatitis B surface antigen by RNA interference therapeutic AB-729 in chronic hepatitis B patients correlates with suppression of all HBsAg isoforms and HBV RNA J Hepatol 2021 75 S760
88 Paratala BS Park JJ Ganchua SC Gane E Yuen MF Lee ACH Inhibition of hepatitis B surface antigen in chronic hepatitis B subjects by RNA interference therapeutic AB-729 is accompanied by upregulation of HBV-specific T cell activation markers J Hepatol 2021 75 S761
89 Yuen MF Lim TH Kim W Tongkijvonich P Yoon JH Sievert W HBV RNAi inhibitor RG6346 in Phase 1b-2a trial was safe, well tolerated, and resulted in substantial and durable reductions in serum HBsAg levels AASLD The Liver Meeting 2017 2020 Nov 11-16 USA
90 Hong J Montero SM Tan H Rajwanshi VK Kang H Sousa J Incorporation of novel siRNA chemistries significantly improves the potency and durability of HBV siRNAs in the AAV-HBV mouse model AASLD The Liver Meeting 2017 2021 Nov 12-15 USA
91 Hong J Montero SM De Costa T Nie Y Tan H Pandey R ALG-125755, a small interfering RNA (siRNA) against hepatitis B virus (HBV) effectively inhibits hepatitis B surface antigen (HBsAg) secretion in HBV cell models and the AAV-HBV mouse model J Hepatol 2021 75 S742
92 Aligos Therapeutics. Aligos Therapeutics to present phase 1 safety and pharmacokinetic data for STOPS™ molecule drug candidate ALG-010133 and several nonclinical chronic hepatitis B programs at the european association for the study of the Liver’s Digital International Liver Congress 2021. Aligos Therapeutics web site, < https://www.globenewswire.com/news-release/2021/06/21/2250190/0/en/Aligos-Therapeuticsto-Present-Phase-1-Safety-and-Pharmacokinetic-Data-forSTOPS-Molecule-Drug-Candidate-ALG-010133-and-SeveralNonclinical-Chronic-Hepatitis-B-Programs-at-the-Euro.html >. Accessed 15 Feb 2022
93 Yuen MF Heo J Kumada H Suzuki F Suzuki Y Xie Q Results after 12 weeks treatment of multiple doses of GSK3389404 in chronic hepatitis B (CHB) subjects on stable nucleos(t)ide therapy in a phase 2a double-blind, placebo-controlled study AASLD The Liver Meeting 2017 2019 Nov 8-11 Boston, USA
94 Yuen MF Heo J Jang JW Yoon JH Kweon YO Park SJ Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial Nat Med 2021 27 1725 1734 34642494
95 Yuen MF Lim YS Cloutier D Thanawala V Shen L Arizpe A Preliminary results from a phase 2 study evaluating VIR-2218 alone and in combination with pegylated interferon Alfa-2a in participants with chronic hepatitis B infection AASLD The Liver Meeting 2017 2021 Nov 12-15 USA
96 Yuen MF Asselah T Jacobson IM Brunetto M Janssen HL Takehara T Efficacy and safety of the siRNA JNJ-3989 and/or the capsid assembly modulator JNJ-6379 for the treatment of chronic hepatitis B virus infection: results from the phase 2b REEF-1 study AASLD The Liver Meeting 2017 2021 Nov 12-15 USA
97 Tan H Kang H Luo M Nie Y Pandey R Montero SM Combination drug interactions of hepatitis B virus (HBV) small interfering RNA (siRNA) and antisense oligonucleotides (ASO) in vitro and in vivo J Hepatol 2021 75 S720
98 Tan H Kang H Hong J Luo M Nie Y Pandey R Triple combination of anti-hepatitis B virus drugs demonstrates synergistic activity in vitro AASLD The Liver Meeting 2017 2021 Nov 12-15 USA
99 Michler T Kosinska AD Festag J Bunse T Su J Ringelhan M Knockdown of virus antigen expression increases therapeutic vaccine efficacy in high-titer hepatitis B virus carrier mice Gastroenterology 2020 158 1762 1775.e9 32001321
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.